Several companies are developing wearable biosensors in the form of wristbands, but the co-founder of biosensing technology company Valencell says the ear is the best to place collect vital signs, and giants Intel and Apple have earbud ambitions as well.
Minnesota's MGC Diagnostics has completed its acquisition of a promising Belgian competitor, putting its plan for global expansion in place less than a month after the M&A deal was first announced.
Stentys announced that it is discontinuing enrollment of its Apposition V trial for its bare metal stent and focusing its resources and money on its next-generation sirolimus-eluting stent featuring a new delivery catheter.
Capnia expects to launch its breath-based device that would make the determination of whether newborn jaundice is a health threat easier and faster. This could potentially cut down the need for infant hospital readmissions due to jaundice.
Amgen put out the word Monday that adding Kyprolis to combo therapy with Celgene's Revlimid beat out the Revlimid combo alone in melanoma patients who had relapsed.
A month ago, Tekmira shares took a deep dive after the FDA placed a clinical hold on its Ebola therapy, the RNAi therapy TKM-Ebola, citing concerns about cytokine release--a condition which can spur a fatal noninfectious fever in the worst cases. The Canadian biotech's shot up more than 12% on Monday morning on speculation that the FDA would put the treatment back on its fast track.
Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.
Amgen put out the word Monday morning that Kyprolis--provided in a combo package with Celgene's Revlimid--beat out Revlimid alone in a head-to-head Phase III study for multiple myeloma, hitting the primary endpoint and offering the Big Biotech a shot at expanding its franchise for the drug at a critical moment in the company's history.
Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.
The technology going into the device, called Rapid Evaporative Ionization Mass Spectrometry, by the Waters Corporation, is a move that one of the developers hopes will give the project new momentum.